Reyon Pharmaceutical Co Ltd (102460) Fair Value & Analysis

Healthcare · KR · Market cap 182B KRW

Below-average quality, and screening another 21% overvalued on our models.

What matters now

• Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
• A fairly wide model range (5,888 KRW to 11,776 KRW) leaves room in how you read the outcome.
• Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 9,770 KRW – 70,413 KRW · fair‑value band 5,888 KRW – 11,776 KRW · the 10,000 KRW price screens above the 7,890 KRW fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Reyon Pharmaceutical Co Ltd (102460) currently trades at 10,000 KRW, while our model-based Fair Value estimate is 7,890 KRW, implying the stock looks roughly 21.1% overvalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Reyon Pharmaceutical Co Ltd generated revenue of 126B KRW at a net margin of 10.7%. Revenue declined 1.9% year over year. It earns a return on equity of 6.8%. Net debt stands at 208B KRW. Fundamentals as of Aug 13, 2026

Our scenario range runs from 5,888 KRW (bear case) to 11,776 KRW (bull case); at 10,000 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -40% fair-value upside, at -21%, 102460 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; …

Full company description

REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study. In addition, the company engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases; and RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Reyon Pharmaceutical Co Ltd reported revenue of 146B KRW in FY2025 versus 143B KRW in FY2021, a compound +0.5%/yr. Reported net income was −29.6B KRW in FY2025.

102460 screens 21% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 638 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.